Ascendia Solidifies Leading CDMO Position By Ranking on Inc. 5000 List Again
Ascendia Pharmaceuticals solidified its position as a leading pharmaceutical contract formulation development and manufacturing organization (CDMO) by once again being ranked in the prestigious Inc. 5000 of the nation’s fastest-growing private companies. Ascendia’s success in developing specialized formulations for poorly water soluble molecules and expanded services that include biologics helped Ascendia rise 3,239 positions on the annual Inc. 5000 list.
Ascendia achieved 333% growth over the past three years, ranking it 1,422 overall in the Inc 5000 rankings. Ascendia was also the 32nd-ranked company in New Jersey and was 130th in the healthcare segment. The list represents the most successful companies within the American economy’s most dynamic segment—its independent small businesses.
Drug Formulations to Make Insoluble Soluble
“Our ascension up the Inc. 5000 rankings shows the commitment Ascendia has to helping its customers overcome the challenges associated with developing parenteral, oral, and topical dosage forms. Our specialized formulation development and early-stage cGMP manufacturing services for these projects helps make the Insoluble Soluble,” said Ascendia founder and CEO Jim Huang, Ph.D.
“We continue to expand our services, such as biologics and the ability to offer fast, flexible, and small-batch size services for first-in-man clinical studies. For example, Ascendia will offer late-stage and commercial cGMP manufacturing in 2022. For these reasons, we are confident that we will continue to meet our growth expectations,” concluded Dr. Huang.
One of Country’s Top Private Companies
Not only have the companies on the 2021 Inc. 5000 been very competitive within their markets. This year’s list, however, also proved especially resilient and flexible given 2020’s unprecedented challenges. Among the 5,000, the average median three-year growth rate soared to 543%, and median revenue reached $11.1 million. Together, those companies added more than 610,000 jobs over the past three years.
Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at https://www.inc.com/inc5000.
“The 2021 Inc. 5000 list feels like one of the most important rosters of companies ever compiled,” says Scott Omelianuk, editor-in-chief of Inc. “Building one of the fastest-growing companies in America in any year is a remarkable achievement. Building one in the crisis we’ve lived through is just plain amazing. This kind of accomplishment comes with hard work, smart pivots, great leadership, and the help of a whole lot of people.”
Contact us to learn how we can be your CDMO for complex drug development projects.Back to articles
Want to learn more about
Get up-to-date informationStay in touch >